Formyl peptide receptor 1 (FPR1) is a high-affinity G-protein coupled receptor (GPCR) predominantly expressed on phagocytic cells. It plays a critical role in mediating immune cell chemotaxis, degranulation, and superoxide production in response to bacterial and host-derived formylated peptides. In oncology, FPR1 is recognized as a key mediator of immunogenic cell death (ICD), where its interaction with tumor-released Annexin A1 (ANXA1) guides dendritic cells to dying cancer cells, orchestrating an effective anti-tumor immune response. Conversely, aberrant FPR1 activation drives chronic inflammatory diseases, neurodegeneration, and tumor progression in certain microenvironments, making it a highly sought-after therapeutic target for both small molecule antagonists and agonistic biologics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FPR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANXA1 Recombinant Protein (FPR1 Ligand) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View ANXA1 Products |
| Gene Delivery | FPR1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Preserves native 7-transmembrane conformation. |
View FPR1 Products |
| Benchmark Ab | Anti-FPR1 Recombinant Antibody Sequence-verified recombinant positive control for FACS and functional blocking. |
View FPR1 Products |
| Validator | FPR1 siRNA Set For knockdown verification in functional assays. |
View FPR1 Products |
| Related Target A | FPR2 (FPRL1) Subfamily homolog. Crucial for off-target selectivity screening and counter-selection. |
View FPR2 Products |
| Related Target B | FPR3 Subfamily homolog. Required for comprehensive selectivity profiling of small molecules and biologics. |
View FPR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of GPCR | High-titer Lentivirus premade particles to establish stable overexpressing host cell lines (e.g., CHO, HEK293) for physiological conformation. |
| Subfamily Off-target Screening | Validated FPR2 and FPR3 reference materials to construct counter-screening selectivity panels. |
| Lack of Controls | Clinical Benchmark Antibodies and sequence-verified positive control ligands included |
| False Positives | Sequence-specific siRNA pools included for target-specific knockdown verification |
Live FPR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of FPR1 is expanding rapidly beyond classic anti-inflammatory indications into oncology and tissue regeneration. In the oncology space, preserving or enhancing FPR1-ANXA1 signaling is critical for the efficacy of anthracycline- and oxaliplatin-based chemotherapies, leading to the development of FPR1 agonists that mimic or enhance ICD. In contrast, in inflammatory disorders such as acute lung injury, rheumatoid arthritis, and cardiovascular reperfusion injury, FPR1 antagonists are being developed to curb excessive neutrophil recruitment. The next wave of R&D focuses on highly selective small molecules and biased GPCR agonists that can selectively trigger pro-resolving pathways without inducing systemic pro-inflammatory cascades.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Bristol Myers Squibb, Academic Institutes | Inflammatory Diseases, Ischemia-Reperfusion Injury | Selectivity Assay (Need FPR1 vs FPR2/FPR3 expressing stable cell lines) |
| Peptide Agonists | Biotech Startups | Wound Healing, Tissue Repair | Functional Signaling Assay (Need high-purity ANXA1 ligand and target overexpressing cells) |
| Monoclonal Antibodies | Oncology-focused Biopharma | Solid Tumors (ICD Enhancement) | Epitope Mapping & Binding (Need sequence-verified extracellular loop mimics or native cell surface expression) |